Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Lantern Pharma (NASDAQ: LTRN), an AI-focused company developing cancer therapies, announced its participation in the upcoming ThinkEquity Conference. The presentation is scheduled for Wednesday, October 30, 2024, at 10:30 a.m. ET and will take place at the Mandarin Oriental in New York, NY. The company's management will be available for one-on-one meetings during the conference. The event can be accessed through provided webcast and registration links, offering investors an opportunity to learn about Lantern's innovative approach to oncology drug discovery and development.
Lantern Pharma (NASDAQ: LTRN), un'azienda focalizzata sull'IA che sviluppa terapie per il cancro, ha annunciato la sua partecipazione alla prossima ThinkEquity Conference. La presentazione è programmata per mercoledì 30 ottobre 2024, alle 10:30 ET e si svolgerà presso il Mandarin Oriental di New York, NY. La direzione dell'azienda sarà disponibile per incontri individuali durante la conferenza. L'evento sarà accessibile tramite i link forniti per la registrazione e la trasmissione in diretta, offrendo agli investitori l'opportunità di conoscere l'approccio innovativo di Lantern nella scoperta e nello sviluppo di farmaci oncologici.
Lantern Pharma (NASDAQ: LTRN), una empresa enfocada en IA que desarrolla terapias contra el cáncer, anunció su participación en la próxima ThinkEquity Conference. La presentación está programada para el miércoles 30 de octubre de 2024, a las 10:30 a.m. ET y tendrá lugar en el Mandarin Oriental en Nueva York, NY. La dirección de la empresa estará disponible para reuniones uno a uno durante la conferencia. El evento se podrá acceder a través de los enlaces proporcionados para la transmisión web y el registro, ofreciendo a los inversores la oportunidad de conocer el enfoque innovador de Lantern en el descubrimiento y desarrollo de medicamentos oncológicos.
란턴 제약 (NASDAQ: LTRN), 암 치료제를 개발하는 AI 중심의 회사가 다가오는 ThinkEquity Conference에 참여한다고 발표했습니다. 프레젠테이션은 2024년 10월 30일 수요일 오전 10시 30분 ET에 뉴욕, NY의 만다린 오리엔탈에서 진행될 예정입니다. 회사 경영진은 컨퍼런스 기간 동안 일대일 미팅을 위해 참석할 것입니다. 이 행사는 제공된 웹캐스트 및 등록 링크를 통해 접근할 수 있으며, 투자자들에게 란턴의 혁신적인 암 치료제 발견 및 개발 접근 방식에 대해 알릴 기회를 제공합니다.
Lantern Pharma (NASDAQ: LTRN), une entreprise axée sur l'IA développant des thérapies contre le cancer, a annoncé sa participation à la prochaine ThinkEquity Conference. La présentation est prévue pour le mercredi 30 octobre 2024, à 10h30 ET et se déroulera au Mandarin Oriental à New York, NY. La direction de l'entreprise sera disponible pour des réunions individuelles pendant la conférence. L'événement sera accessible via les liens fournis pour le webinaire et l'inscription, offrant aux investisseurs une occasion d'en apprendre davantage sur l'approche innovante de Lantern dans la découverte et le développement de médicaments oncologiques.
Lantern Pharma (NASDAQ: LTRN), ein auf KI fokussiertes Unternehmen, das Krebs-Therapien entwickelt, hat seine Teilnahme an der bevorstehenden ThinkEquity Conference angekündigt. Die Präsentation ist für Mittwoch, den 30. Oktober 2024, um 10:30 Uhr ET geplant und findet im Mandarin Oriental in New York, NY, statt. Das Management des Unternehmens wird während der Konferenz für Einzelgespräche zur Verfügung stehen. Die Veranstaltung kann über die bereitgestellten Links für die Webübertragung und die Registrierung erreicht werden, was den Investoren die Möglichkeit bietet, mehr über den innovativen Ansatz von Lantern bei der Entdeckung und Entwicklung von Onkologika zu erfahren.
- None.
- None.
- Webcast Link: https://www.meetmax.com/sched/event_106721/conference_register.html
- Conference Registration Link: https://www.wsw.com/webcast/tep25/ltrn/1700352
Lantern Pharma management will be available for one-on-one meetings held throughout the conference.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately
Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over
Please find more information at:
- Website: www.lanternpharma.com
- LinkedIn: https://www.linkedin.com/company/lanternpharma/
- X: @lanternpharma
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," “model,” "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (iv) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (v) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023735245/en/
Investor Contact:
ir@lanternpharma.com
Source: Lantern Pharma Inc.
FAQ
When is Lantern Pharma (LTRN) presenting at the ThinkEquity Conference in 2024?
Where will the ThinkEquity Conference featuring Lantern Pharma (LTRN) be held?
How can investors attend Lantern Pharma's (LTRN) presentation at the ThinkEquity Conference?